Karuna Therapeutics, Inc. - Common Stock (NQ:KRTX)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Karuna Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Beyond Tech And AI: Why The Sector Hedge Funds Prefer Is Not The One You'd Expect ↗

February 27, 2024

Hedge funds are shifting towards stability and value by favoring the health care sector over booming tech stocks.

Via Benzinga

Karuna Therapeutics: Q4 Earnings Insights ↗

February 22, 2024

Via Benzinga

Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update

February 22, 2024

From Karuna Therapeutics, Inc.

Via Business Wire

Mental Health Mavericks: 3 Stocks Changing the Game ↗

February 21, 2024

Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money.

Via InvestorPlace

This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space ↗

February 16, 2024

Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset...

Via Benzinga

Mizuho Downgrades Karuna Therapeutics: Here's What You Need To Know ↗

January 26, 2024

Via Benzinga

KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX

February 14, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst ↗

February 06, 2024

UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy.

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Catalent, Inc. (NYSE – CTLT), Everbridge, Inc. (Nasdaq – EVBG), Slam Corp. (Nasdaq – SLAM), Karuna Therapeutics, Inc. (Nasdaq – KRTX)

February 05, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB), Exro Technologies Inc. (OTC – EXROF), Karuna Therapeutics, Inc. (Nasdaq – KRTX)

January 30, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc. (Nasdaq – KRTX), Carrols Restaurant Group, Inc. (Nasdaq - TAST), Ansys, Inc. (Nasdaq - ANSS), HomeStreet, Inc. (Nasdaq - HMST)

January 26, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

ABBV: This Top Biotech Just Went On A Buying Spree ↗

January 25, 2024

AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel).

Via Talk Markets

January 22, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Bullish Continuation In '24? 3 Market Areas To Watch ↗

January 10, 2024

This article discusses 3 market areas that should outperform dramatically over the next 12 months...

Via Talk Markets

5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday ↗

January 08, 2024

The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.

Via Benzinga

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)

January 04, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX

December 31, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals

December 29, 2023

Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio.

Via MarketBeat

Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review ↗

December 29, 2023

The major indexes boast big annual gains with the Dow at record highs.

Via Investor's Business Daily

Topics Stocks

Microsoft To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Thursday ↗

December 28, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

December 26, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Bristol-Myers' Acquisition Of Karuna Therapeutics Paves Way For Aggressive Global Marketing Of KarXT: Analyst ↗

December 26, 2023

H.C.

Via Benzinga

Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100% ↗

December 26, 2023

Bristol Myers Squibb said it would acquire cancer drug developer RayzeBio in a $4.1 billion deal. RYZB stock soared; BMY stock traded slightly lower.

Via Investor's Business Daily

Why Is RayzeBio (RYZB) Stock Up 100% Today? ↗

December 26, 2023

RYZB stock has doubled today after Bristol Myers Squibb shelled out $4.1 billion to buy RayzeBio. Expect more such deals in 2024.

Via InvestorPlace

Cognizant Technology Solutions To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

December 26, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

December 25, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 25, 2023

Via Benzinga

Bristol-Myers Buying Karuna Signals A Biotech Boom Ahead: Jefferies ↗

December 24, 2023

Bristol-Myers Squibb is buying Karuna Therapeutics for $14 billion. Karuna Therapeutics Inc stock jumped nearly 50% on Friday. Jefferies analyst Michael Yee shares his view on biotech stocks.

Via Talk Markets

Dow Edges Lower; Nike Sales Miss Estimates ↗

December 22, 2023

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning lower on Friday. The Dow traded down 0.05% to 37,385.32 while the NASDAQ rose 0.12% to 14,982.36. The S&P 500 also...

Via Benzinga

Topics Earnings Stocks

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.